RNLX Renalytix AI ADS

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit .

For further information, please contact:

Renalytix plc
James McCullough, CEOVia Walbrook PR
  
Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea 
  
Investec Bank plc (Joint Broker)Tel: 020 7597 4000
Gary Clarence / Shalin Bhamra 
  
Walbrook PR LimitedTel: 020 7933 8780 or
Paul McManus / Alice WoodingsMob: 07980 541 893 / 07407 804 654
  
CapComm Partners 
Peter DeNardo



Tel: 415-389-6400 or


EN
09/02/2024

Underlying

RNLXRenalytix AI ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Renalytix AI ADS

 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Commencement of trading on OTCQB in the United States

Commencement of trading on OTCQB in the United States Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depo...

October 8, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collab...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno’), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chro...

July 11, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard t...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings p...

June 27, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Medicare Issues Final Coverage Determination for kidneyintelX.dkd Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the Company's kidneyintelX.dkd testing. The final LCD can be accessed at , and is effective for dates of service on or after August 1, 2024. The established Medicare price for...

June 14, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage...

May 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch